Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited)

v3.19.3
Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Other Comprehensive Loss
Beginning balance at Dec. 31, 2017 $ 7,904   $ 3 $ 110,265 $ (102,017) $ (347)
Beginning balance (in shares) at Dec. 31, 2017     24,559      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares 138     138    
Exercise of stock options, net of vesting of restricted shares (in shares)     248      
Issuance of common stock, net of issuance costs 9,564     9,564    
Issuance of common stock, net of issuance costs (in shares)     1,086      
Stock-based compensation expense 285     285    
Cumulative translation adjustment (43)         (43)
Net loss (6,212)       (6,212)  
Ending balance at Sep. 30, 2018 11,636   $ 3 120,252 (108,229) (390)
Ending balance (in shares) at Sep. 30, 2018     25,893      
Beginning balance at Jun. 30, 2018 15,097   $ 3 120,177 (104,709) (374)
Beginning balance (in shares) at Jun. 30, 2018     25,871      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares 11     11    
Exercise of stock options, net of vesting of restricted shares (in shares)     22      
Common stock issuance costs (10)     (10)    
Stock-based compensation expense 74     74    
Cumulative translation adjustment (16)         (16)
Net loss (3,520)       (3,520)  
Ending balance at Sep. 30, 2018 11,636   $ 3 120,252 (108,229) (390)
Ending balance (in shares) at Sep. 30, 2018     25,893      
Beginning balance at Dec. 31, 2018 5,827 $ 5,377 $ 3 118,062 (111,820) (418)
Beginning balance (in shares) at Dec. 31, 2018   6 27,253      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares 165     165    
Exercise of stock options, net of vesting of restricted shares (in shares)     298      
Vesting of restricted stock (in shares)     23      
Exercise of common stock warrants for cash 6,184     6,184    
Exercise of common stock warrants for cash (in shares)     617      
Exercise of common stock warrants pursuant to cashless provisions 0   $ 1 (1)    
Exercise of common stock warrants pursuant to cashless provisions (in shares)     10,913      
Series A convertible preferred stock redeemed for cash (863) $ (5,377)   (863)    
Series A convertible preferred stock redeemed for cash (in shares)   (6)        
Waiver of sponsor promissory note originally issued in conjunction with Reverse Merger and Recapitalization 1,993     1,993    
Stock-based compensation expense 1,111     1,111    
Cumulative translation adjustment (36)         (36)
Net loss (8,987)       (8,987)  
Ending balance at Sep. 30, 2019 6,481   $ 4 126,651 (119,720) (454)
Ending balance (in shares) at Sep. 30, 2019     39,104      
Beginning balance at Jun. 30, 2019 8,143   $ 4 125,854 (117,294) (421)
Beginning balance (in shares) at Jun. 30, 2019     38,902      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Exercise of stock options, net of vesting of restricted shares 113     113    
Exercise of stock options, net of vesting of restricted shares (in shares)     179      
Vesting of restricted stock (in shares)     23      
Stock-based compensation expense 684     684    
Cumulative translation adjustment (33)         (33)
Net loss (2,426)       (2,426)  
Ending balance at Sep. 30, 2019 $ 6,481   $ 4 $ 126,651 $ (119,720) $ (454)
Ending balance (in shares) at Sep. 30, 2019     39,104